ENSURING COMPLIANCE FOR PAMA REIMBURSEMENT PROTOCOLS FOR CLINICAL LABORATORY TESTS

As required under the Protecting Access to Medicare Act (PAMA) of 2014, CMS recently issued the final requirements to establish a modern payment and reimbursement system for clinical diagnostic laboratory tests (CDLT) under the clinical lab fee schedule (CLFS). The guidance implements noteworthy payment and policy changes for CDLTs; however, prior processes such as gapfill and crosswalk will continue for some tests. CMS deferred the implementation of the requirements until 2018 as the repercussions of these regulations will entail labs to dedicate substantial time and resources to fully comply. While CMS has provided significant perspective on the novel market-based system, industry reimbursement teams anxiously await further instruction on registration, reporting and operational procedures.

• Claims and reporting timelines for CLDT and ALDT
• Definitions and interpretations of a “reporting entity”
• Qualifying “new information” for ALDT and MAAAs
• Methods for accurate implementation and data collection

Speaker:
Jane Pine Wood
Member
McDonald Hopkins LLC

Contact:

Brooke Akins | Manager, Market Intelligence | 312.224.1693 webinars@q1productions.com